Wilson's Disease with Psychosis or Hallucinations: When First-Line Antipsychotic Treatment Has Not Worked

Clinical Scenario

Wilson's disease can present with significant psychiatric features, including psychosis and hallucinations. When these symptoms occur, antipsychotic therapy is initiated — preferring agents with a low risk of extrapyramidal and hepatic adverse effects. However, not all patients achieve adequate symptom control on first-line treatment, and a structured next step is required.

First-Line Treatment — Insufficient Response

First-line management with second-generation antipsychotics — quetiapine, olanzapine, or aripiprazole, with clozapine reserved for the most severe cases — did not achieve the clinical goal of improvement or resolution of psychosis and hallucinations. The protocol below addresses what comes next.

Second-Line Approach — Partial Overview

Second-line antipsychotic therapy is indicated for patients who have not responded sufficiently to first-line agents. The specific agents indicated at this stage, and full clinical guidance, are available in the complete protocol.

Treatment Goal

Improvement and resolution of psychosis and hallucinations.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.jhep.2024.11.007

Quetiapine and clozapine are neuroleptics associated with low risk of extrapyramidal symptoms, as well as low hepatic risk, and could be recommended as the first-line treatment for psychosis.

Antipsychotic/amisulpride 200–800 mg; sulpiride 200–800 mg, second line.

View source ↗